Papers/PMID:41023483
Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Nature medicine2025The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
Cannabis sativa — no detected effect on serious adverse event incidence
Evidence strength: moderate.FindingNull result“The rate of serious adverse events (SAEs) was comparable between VER-01 and placebo (6.2% versus 6.8%; P = 0.699; Table 3).”
Quoted verbatim from Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. - Study
- RCT
- Duration
- 3 months
- Dose
- Individually titrated over 3 weeks, up to a maximum of 13 dose units (119 µl each) per day, morning and evening
- Population
- Adults with chronic low back pain in the 12-week double-blind placebo-controlled phase A safety analysis (VER-01 n = 390; placebo n = 425)
Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.2025PMID:4102348310.1038/s41591-025-03977-0An author is affiliated with a producerPermalink